Aerie Pharmaceuticals (AERI) Stock Price, News & Analysis

Company Overview

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $15.25 to $15.25
• 50-Day Range: $15.18 to $15.25
• 52-Week Range: $4.81 to $15.37
• Volume: 600 shs
• Average Volume: 974,748 shs
• Market Capitalization: $753.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AERI Stock Analysis - Frequently Asked Questions

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.62) by $0.10. The firm earned $29.31 million during the quarter, compared to analyst estimates of $29.13 million.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aerie Pharmaceuticals investors own include Canopy Growth (CGC), Nicox (NICXF), Bristol-Myers Squibb (BMY), Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE) and Melinta Therapeutics (MLNT).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AERI
• CUSIP: N/A
• CIK: 1337553
• Web: www.aeriepharma.com
• Phone: (919) 237-5300
• Fax: 949-526-8787
• Employees: 376
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-74,810,000.00
• Net Margins: -17.09%
• Pretax Margin: -16.47%
• Return on Equity: N/A
• Return on Assets: -2.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.27
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $194.13 million
• Price / Sales: 3.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.32) per share
• Price / Book: -4.59

Miscellaneous

• Outstanding Shares: 49,417,000
• Free Float: 47,223,000
• Market Cap: $753.61 million
• Optionable: Optionable
• Beta: -0.06